Eloralintide
A once-weekly amylin-receptor agonist from Lilly that produced GLP-1-like weight loss on its own in a phase 2 trial.
Investigational (Eli Lilly); not approved.
Used for
- Weight loss
- Fullness after meals
How it works
Amylin is released with insulin and signals fullness in the brainstem and slows the stomach. Eloralintide targets amylin receptors selectively (cagrilintide also hits calcitonin receptors).
What the research shows
- Phase 1 (12 weeks, 100 people, no dose stepping): stomach side effects were infrequent; lower appetite, headache and fatigue were the most common.
- Phase 2 (48 weeks, 263 people without diabetes): weight fell 9% on 1 mg, 12% on 3 mg, 18% on 6 mg and 20% on 9 mg weekly, vs 0.4% on placebo.
- Nausea (11–64% depending on dose and stepping) and fatigue rose with dose; starting low and stepping up helped.
Dosing
Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.
Work out the units to draw for your vial →Side effects
- Nausea, higher with bigger doses
- Fatigue
- Lower appetite
- Headache
Cautions
- Still in trials: long-term safety is unknown.
- On insulin? Amylin drugs add to its effect and can cause low blood sugar: only with your doctor.
- With a GLP-1, side effects add up: step each one separately.
- Research-chemical vials have no quality control: purity, dose and sterility vary. Third-party testing helps but is no guarantee.
Storage
Unmixed powder: freezer or fridge, away from light.
Once mixed with bacteriostatic water: fridge; the common rule is to use it within 28 days.
There is no label or published stability data for this one, so treat these as habits, not limits.
More in Weight & metabolic
Reference only, not medical advice. Written for this app from the cited research. Doses marked community-reported are not from trials.